3 completed, 1 active not recruiting, 1 recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Endeavor Biomedicines, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants taladegib, nintedanib, pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 1 | Recruiting | Endeavor Biomedicines, Inc. | 57 | 2026-04-28 | 2026-05-15 |
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Active not recruiting | Endeavor Biomedicines, Inc. | 213 | 2024-11-15 | 2026-02-24 |
| A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects taladegib, nintedanib - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Endeavor Biomedicines, Inc. | 21 | 2023-05-03 | 2023-12-15 |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations ENV-101 (taladegib) - Solid Tumors With PTCH1 Loss-of-function Mutations | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 20 | 2022-05-24 | 2026-03-05 |
| A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) taladegib, placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 41 | 2021-08-26 | 2024-12-02 |
Idiopathic Pulmonary Fibrosis (4) · Pulmonary Fibrosis (3) · Adenoma, Islet Cell (1) · Glioma (1) · Laryngeal Diseases (1) · Medulloblastoma (1) · Melanoma (1) · Mesothelioma (1) · Neuroblastoma (1) · Osteosarcoma (1) · Pituitary Diseases (1) · Retinoblastoma (1) · Rhabdomyosarcoma (1) · Sarcoma (1) · Uveal Melanoma (1)
LY2940680 (5) · nintedanib (2) · pirfenidone (1)
Australia (4) · Canada (2) · Malaysia (2) · Mexico (2) · South Korea (2) · Argentina (1) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · New Zealand (1) · United Kingdom (1) · United States (1)
Lisa Lancaster, M.D. (3) · John Huetsch, M.D. (1) · Paul Frohna, M.D., Ph.D. (1)